Every material Form 8-K American Healthcare REIT filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
American Healthcare REIT reported third quarter 2025 net income attributable to its controlling interest of $55.9 million, or $0.33 per diluted share, compared with a loss of $4.1 million a year earlier, and raised its full-year 2025 guidance. The company's full-year NFFO guidance now runs from $1.69 to $1.72 per share, up from $1.64 to $1.68, which gives shareholders a higher expected earnings base for 2025.
Q3 2025 revenue was $572.9 million, up from $523.8 million in Q3 2024; net income attributable to controlling interest was $55.9 million, or $0.33 per diluted share, versus a loss of $4.1 million, or $0.03 per share.
Q3 2025 NFFO was $0.44 per diluted share, compared with $0.36 in Q3 2024.
2025 NFFO guidance was raised to $1.69 to $1.72 per share from $1.64 to $1.68; total portfolio same-store NOI growth guidance was raised to 13.0% to 15.0% from 11.0% to 14.0%.
Net debt to annualized adjusted EBITDA improved to 3.5x as of September 30, 2025, from 3.7x as of June 30, 2025.
American Healthcare REIT, Inc. entered an ATM Equity Offering Sales Agreement on August 8, 2025, allowing it to sell up to $1 billion of common stock through a group of sales agents, replacing its prior at-the-market program. Shares may be sold at times the company chooses, and the company says net proceeds will go to its Operating Partnership for general corporate purposes, which may include repaying debt. Sales could dilute existing shareholders, but the filing does not say whether or when any shares will be sold.
Program covers up to $1 billion aggregate gross sales price of common stock, $0.01 par value
Agents may earn commissions up to 2.0% of gross sales price of shares sold
Prior at-the-market program, dated November 18, 2024, was terminated with no shares left unsold
Shares offered under a prospectus supplement dated August 8, 2025 and a shelf registration on Form S-3
American Healthcare REIT (NYSE: AHR) reported second quarter 2025 results on August 7, 2025, with total revenues of $542.5 million, up from $504.6 million a year earlier, and net income attributable to controlling interest of $9.9 million, or $0.06 per diluted share. The company raised its full year 2025 guidance for NFFO per diluted share and total portfolio Same-Store NOI growth, citing strong operating results in its ISHC and SHOP segments.
Q2 NFFO was $0.42 per diluted share, compared with $0.33 in the second quarter of 2024; GAAP net income was $0.06 per diluted share, compared with $0.01.
2025 NFFO per diluted share guidance rose to $1.64 to $1.68 from $1.58 to $1.64; total portfolio Same-Store NOI growth guidance rose to 11.0% to 14.0% from 9.0% to 13.0%.
Net Debt-to-Annualized Adjusted EBITDA improved to 3.7x as of June 30, 2025, from 4.5x as of March 31, 2025; total liquidity was about $733.5 million.
The Board declared a $0.25 per share distribution for the quarter ended June 30, 2025, paid on or about July 18, 2025.
American Healthcare REIT reported first quarter 2025 total revenues of $540.6 million, up from $499.5 million a year earlier, and raised its full-year 2025 guidance. GAAP net loss attributable to controlling interest widened to $6.8 million, or $(0.04) per diluted share, from $3.9 million a year earlier, mainly due to a $21.7 million impairment of a real estate investment. Shareholders get higher expected 2025 normalized FFO, but a larger GAAP loss in the quarter.
Total revenues were $540.6 million for the quarter ended March 31, 2025, compared with $499.5 million for the same period in 2024.
Normalized FFO attributable to common stockholders was $0.38 per diluted share, up from $0.30 a year earlier.
Full-year 2025 normalized FFO guidance was raised to $1.58 to $1.64 per diluted share from $1.56 to $1.60; total portfolio same-store NOI growth guidance rose to 9.0% to 13.0% from 7.0% to 10.0%.
Net loss attributable to controlling interest was $(6.8) million, compared with $(3.9) million a year earlier, after a $21.7 million impairment of a real estate investment.
American Healthcare REIT reported fourth-quarter and full-year 2024 results on February 27, 2025, and issued full-year 2025 guidance. The fourth-quarter GAAP net loss per diluted share narrowed to $(0.21) from $(0.42) a year earlier, and normalized FFO per diluted share rose to $0.40 from $0.38, while full-year normalized FFO was $1.41 versus $1.40 in 2023. For 2025, the company expects normalized FFO of $1.56 to $1.60 per diluted share and total portfolio same-store NOI growth of 7.0% to 10.0%.
Q4 2024 GAAP net loss attributable to controlling interest was $(31.8) million, or $(0.21) per diluted share, versus $(27.4) million, or $(0.42), in Q4 2023.
Full-year 2024 normalized FFO was $1.41 per diluted share; total portfolio same-store NOI grew 17.7%.
2025 guidance: normalized FFO of $1.56 to $1.60 per diluted share and net income of $0.26 to $0.30 per diluted share, versus a 2024 net loss of $(0.29).
Company raised about $1.36 billion of gross equity in 2024, including $120.2 million through its at-the-market program in Q4.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every American Healthcare REIT filing is on SEC EDGAR ↗. 8-K briefs of other companies →